Friday - May 29, 2026

Category Archives: Science

Bronchiectasis Clinical Pipeline Demonstrates Strong Growth Backed by 15+ Active Industry Players | DelveInsight

DelveInsight’s, “Bronchiectasis Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the Bronchiectasis pipeline drug profiles, including Bronchiectasis clinical trials and nonclinical stage products. It also covers the Bronchiectasis … Continue reading →

Multiple Sclerosis Treatment Pipeline Witnesses Strong Innovation with 75+ Companies Advancing Novel Therapeutics | DelveInsight

DelveInsight’s “Multiple Sclerosis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Graves’ Disease Therapeutics Market Size (7MM) was ~USD 4,400 million in 2023 and is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Graves’ Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves’ Disease, historical and forecasted epidemiology as well as the Graves’ Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the … Continue reading →

MASH Therapeutics Market Size (7MM) was ~USD 3 Billion in 2025 and it is projected to grow at a significant CAGR by 2036, estimates Delveinsight

DelveInsight’s “MASH Treatment Market Insights, Epidemiology, and Market Forecast – 2036” report delivers an in-depth understanding of MASH, historical and forecasted epidemiology, as well as the MASH market trends in the United States, EU4 (Germany, France, Italy, and Spain) and … Continue reading →

Osteoarthritis Pipeline Continues Rapid Expansion with 100+ Companies Advancing Musculoskeletal Programs | DelveInsight

DelveInsight’s, “Osteoarthritis Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Osteoarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product … Continue reading →

Paroxysmal Nocturnal Hemoglobinuria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Paroxysmal Nocturnal Haemoglobinuria Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Paroxysmal Nocturnal Hemoglobinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Postoperative Acute Pain Market is Expected to Witness Significant Growth by 2036 Driven by Emerging Non-opioid Therapies and Multimodal Pain Management Approaches | DelveInsight

The market dynamics for Postoperative Acute Pain are witnessing steady growth driven by the Increasing Number of Surgical Procedures, Rising Demand for Non-opioid Analgesics, Growing Adoption of Multimodal Pain Management Strategies, and Advancements in Long-acting Local Anesthetic Therapies. Additionally, the … Continue reading →

Mild Cognitive Impairment Market to Witness Robust Growth Through 2036 Driven by Rising Aging Population and Emerging Disease-Modifying Therapies | DelveInsight

The Mild Cognitive Impairment (MCI) market is expected to grow significantly during the forecast period owing to the increasing aging population, rising awareness and early diagnosis, expanding use of biomarker-based diagnostics, and the emergence of disease-modifying therapies. Additionally, the launch … Continue reading →

Intracranial Hemorrhage Market is Expected to Witness Significant Growth by 2036 Due to Advancements in Acute Care Therapies and Emerging Neuroprotective Approaches | DelveInsight

The market dynamics for Intracranial Hemorrhage (ICH) are witnessing steady growth driven by the Increasing Incidence in Aging Populations, Rising Diagnosis and Hospitalization Rates, Growing Use of Anticoagulation Reversal Agents, and Advancements in Acute Neurocritical Care and Minimally Invasive Surgical … Continue reading →

Cushing Syndrome Clinical Trial Pipeline Expands with Robust Contributions from 4+ Global Biopharma Companies | DelveInsight

DelveInsight’s “Cushing Syndrome Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →